pirenoxine (Catalin)

01/01/1987 - "In the two long-term double blind studies on humans described here, comparing BA, placebo and Catalin in the topical treatment of progressive cataract rapid (2-3 weeks treatment) reversal of incipient cataract was obtained accompanied by a marked improvement of vision and by a significantly lower percentage of eyes requiring surgery after 22 months treatment with BA than with placebo and Catalin. "
01/01/2010 - "[Efficacy of catalin eyed drops in age-related cataract agents]."
01/01/2011 - "Further studies on formulation modifications of catalin and recommended doses of PRX to optimize clinical efficacy by cataract type are warranted."
04/01/1978 - "Hypoglycaemic effect of 'Catalin' an anti-cataract agent in rabbits, (a preliminary study)."
08/21/2022 - "The Possible Positive Mechanisms of Pirenoxine in Cataract Formation."

01/01/1999 - "Animal study on the effects of catalin on aftercataract and posterior capsule opacification."

01/01/2017 - "We screened certain compounds possibly related to lens degeneration and identified pirenoxine, which has been used for cataracts, as a possible new pharmacologic treatment for presbyopia. "
04/16/2020 - "Author Correction: Suppression of presbyopia progression with pirenoxine eye drops: experiments on rats and non-blinded, randomized clinical trial of efficacy."
01/01/2017 - "Pirenoxine eye drops might be a new and the first pharmacologic treatment for preventing progression of presbyopia."
01/01/2017 - "In a parallel randomized controlled clinical study of the subjects in their fifth decade of life, the objective accommodative amplitude (AA) decreased significantly (p < 0.01) by 0.16 diopter (D) in the control group, and there was no detectable change in the treatment group after a 6-month treatment period, suggesting that pirenoxine eye drops might prevent progression of presbyopia. "
01/01/2017 - "Suppression of presbyopia progression with pirenoxine eye drops: experiments on rats and non-blinded, randomized clinical trial of efficacy."

03/01/1962 - "[Long period treatment of retinitis pigmentosa with catalin]."

01/05/2011 - "Two light sources, one centered within (392 nm) and the other centered outside (850 nm) of an absorption band of Pirenoxine Sodium, a common type of drugs in eye disease treatment, were used for dual-wavelength iris imaging measurement. "